Presence of small residual malignant lesions in pathologic complete response after neo-adjuvant chemotherapy in patients with breast cancer
Corresponding Author
Madoka Iwase MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan
Correspondence
Madoka Iwase, Department of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan.
Email: [email protected]
Search for more papers by this authorMasaya Hattori MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorMasataka Sawaki MD, PhD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorAkiyo Yoshimura MD, PhD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorHaruru Kotani MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorNaomi Gondo MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorYayoi Adachi MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorAyumi Kataoka MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorSakura Onishi MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorKayoko Sugino MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorNanae Horisawa MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorMakiko Mori MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorMitsuo Terada MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorHiroji Iwata MD, PhD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorCorresponding Author
Madoka Iwase MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan
Correspondence
Madoka Iwase, Department of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan.
Email: [email protected]
Search for more papers by this authorMasaya Hattori MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorMasataka Sawaki MD, PhD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorAkiyo Yoshimura MD, PhD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorHaruru Kotani MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorNaomi Gondo MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorYayoi Adachi MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorAyumi Kataoka MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorSakura Onishi MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorKayoko Sugino MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorNanae Horisawa MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorMakiko Mori MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorMitsuo Terada MD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this authorHiroji Iwata MD, PhD
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Search for more papers by this author
REFERENCES
- 1Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008; 26(5): 778-785.
- 2Kuerer HM, Vrancken Peeters M, Rea DW, Basik M, De Los SJ, Heil J. Nonoperative management for invasive breast cancer after neoadjuvant systemic therapy: conceptual basis and fundamental international feasibility clinical trials. Ann Surg Oncol. 2017; 24(10): 2855-2862.
- 3Houssami N, MacAskill P, Von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012; 48(18): 3342-3354.
- 4von Minckwitz G, Untch M, Blohmer J-U, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30(15): 1796-1804.
- 5Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17(2): 460-469.
- 6Sabatier R, Sabiani L, Zemmour C, et al. Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis. Breast. 2016; 27: 8-14.
